Results 31 to 40 of about 11,074 (164)

Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for ALK-Rearranged NSCLC—A Case Report

JTO Clinical and Research Reports, 2023
The emergence of spontaneous nonmalignant chylous effusions during treatment with various tyrosine kinase inhibitors (TKIs) has been previously described; however, there have been no prior reports for alectinib.
Sunanjay Bajaj, MD, Andrew Chow, MD, PhD, Alexander Drilon, MD, Or Kalchiem-Dekel, MD   +3 more
doaj   +1 more source

Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report

Thoracic Cancer, 2022
This study presents the first detailed pharmacokinetic data of alectinib and its metabolite M4 in a patient with anaplastic lymphoma kinase (ALK)‐rearranged lung adenocarcinoma undergoing hemodialysis. When the patient was administered a daily 300 mg bid
Ji Eun Park, Young‐Ran Yoon, Chang Ho Kim, Jaehee Lee   +3 more
doaj   +1 more source

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer

Frontiers in Pharmacology, 2022
Molecular targeting therapy is becoming the standard of care for some patients with anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma. Drug-related pneumonitis (DRP) has been identified as an infrequent but potentially severe adverse effect.
Xianmeng Chen, Daqing Xia, Xuqin Jiang, Lejie Cao, Jay H. Ryu, Xiaowen Hu   +5 more
doaj   +1 more source

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China

Thoracic Cancer, 2022
Background There is limited data on the clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in a real‐world setting for Chinese patients with advanced ALK+ NSCLC.
Zihua Zou, Xuezhi Hao, Cuiying Zhang, Haojing Li, Guilan Dong, Yumei Peng, Kewei Ma, Ye Guo, Li Shan, Yan Zhang, Li Liang, Yangchun Gu, Puyuan Xing, Junling Li   +13 more
doaj   +1 more source

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)

, 2022
Anaplastic lymphoma kinase (ALK)-positive lung cancer is a rare cancer that occurs in approximately 5% of non-small-cell lung cancer (NSCLCs) patients. Despite the excellent efficacy of ALK-tyrosine kinase inhibitor in ALK-positive NSCLCs, most patients ...
Toshiya Fujisaki, Tomosue Kajiwara, Toshiaki Kikuchi, Ryo Suzuki, Satoru Miura, Yuka Goto, Yu Saida, Jun Koshio, Aya Ohtsubo, Ami Aoki, Kazuto Nishio, Tetsuya Abe, Koichiro Nozaki, Tomohiro Tanaka, Kazuko Sakai, Tomoki Sekiya, Akira Ishida, Satoshi Shoji, Hirohisa Yoshizawa, Kenichi Koyama, Naohiro Yanagimura, Kohei Kushiro, Daisuke Ishikawa, Satoshi Watanabe, Naoya Matsumoto   +24 more
core   +1 more source

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.

PLoS ONE, 2020
The aim of the study is to evaluate the cost-effectiveness of alectinib for first-line treatment of ALK+ advanced non-small-cell lung cancer compared to crizotinib in the French setting.
Marine Sivignon, Rémi Monnier, Bertrand Tehard, Stéphane Roze   +3 more
doaj   +1 more source

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC

Case Reports in Oncology, 2021
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effusions and
Maiken Parm Ulhoi, Boe Sandahl Sorensen, Peter Meldgaard   +2 more
doaj   +1 more source

Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib. [PDF]

, 2018
To compare the overall survival of anaplastic lymphoma kinase-positive non-small-cell lung cancer patients who received alectinib with those who received ceritinib.Two treatment arms (alectinib [n = 183] and ceritinib [n = 67]) were extracted from ...
Delmar, Paul, Coudert, Mathieu, Martinec, Michael, Golding, Sophie, Crane, Gracy, Martina, Reynaldo, Davies, Jessica, Bordogna, Walter   +7 more
core   +1 more source

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?

, 2018
In the present editorial we describe the therapeutic achievements in the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We focus on the major breakthroughs we have been witnessing in this
Giulio Metro, Alfredo Addeo
core   +1 more source

Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer [PDF]

, 2017
BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC).
Morcos, P.N., Shirish Gadgeel, Ahn, Jin S., Lwin, Zarnie, Noe, J., Bogdana Balas, Dziadziuszko, Rafal, Gadgeel, S., Mok, T., Kim, Dong-Wan, Ahn, Jin Seop, Morcos, P. N., Rafal Dziadziuszko, Johannes Noe, Shaw, A.T., ALEX Trial Investigators, Mok, Tony, Shaw, Alice T., Alice T. Shaw, Rosell, Rafael, Peter N. Morcos, Zeaiter, A., Rosell, R., Pérol, M., Mitry, Emmanuel, Zeaiter, Ali, Tony Mok, Maurice Pérol, Dong-Wan Kim, Ou, S.I., Camidge, D. Ross, Sophie Golding, Peters, Solange, Morcos, Peter N., D. Ross Camidge, Ou, S. H. I., Ahn, J.S., Sai-Hong I. Ou, Camidge, D.R., Perol, Maurice, Camidge, David Ross, Emmanuel Mitry, Gadgeel, Shirish, Solange Peters, Shaw, A. T., Kim, D.W., Noe, Johannes, Golding, Sophie, Balas, Bogdana, Golding, S., Ou, Sai-Hong I., Dziadziuszko, R., Peters, S., Mitry, E., Balas, B., Ali Zeaiter, Jin S. Ahn, Rafael Rosell   +57 more
core   +1 more source